遗传学：KRAS 突变在化疗耐药性结直肠癌中的预测价值。
Genetics: Predictive value of KRAS mutations in chemoresistant CRC.
作者信息
Lièvre Astrid, Laurent-Puig Pierre
机构信息
INSERM Laboratory, Paris, France.
出版信息
Nat Rev Clin Oncol. 2009 Jun;6(6):306-7. doi: 10.1038/nrclinonc.2009.69.
PMID:19483733
Abstract
On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.
摘要
根据卡拉佩蒂斯等人开展的CO.17随机、对照、III期研究的KRAS分析结果，KRAS突变已成为一种有效的预测标志物，与化疗耐药性结直肠癌患者对西妥昔单抗的耐药性以及使用这种抗表皮生长因子受体（EGFR）抗体治疗缺乏生存获益相关。
Zotero 插件